Literature DB >> 1636804

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment.

M E Thase1, A D Simons, J McGeary, J F Cahalane, C Hughes, T Harden, E Friedman.   

Abstract

OBJECTIVE: The authors studied the risk of relapse among depressed patients after cognitive behavior therapy in order to document the need and potential indications for longer-term models of treatment.
METHOD: Forty-eight patients with major depression who responded during a 16-week course of cognitive behavior therapy entered a 1-year prospective follow-up study, as did two patients who received 20 weeks of therapy. Standardized, independent clinical assessments were completed 1, 3, 6, 9, and 12 months after treatment. Relapse was defined as, at minimum, a 2-week period in which the subject met the DSM-III-R criteria for major depression and had a Hamilton depression scale score of 15 or more.
RESULTS: Sixteen patients (32%) relapsed during the 1-year follow-up. Correlates of relapse included a history of depressive episodes, higher levels of depressive symptoms and dysfunctional attitudes, slower response to therapy, and being unmarried. Patients who fully recovered during therapy (Hamilton depression score of 6 or less for 8 weeks or more) were at significantly lower risk for relapse than those who partially recovered (9% and 52%, respectively). Slower response to therapy, unmarried status, and high residual scores on the Dysfunctional Attitudes Scale were independently and additively related to increased risk of relapse.
CONCLUSIONS: These findings provide further evidence of a relation between residual symptoms and relapse after cessation of active treatment. The authors strongly recommend that models of longer-term psychotherapy be developed for depressed patients who do not recover fully during time-limited cognitive behavior therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1636804     DOI: 10.1176/ajp.149.8.1046

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  48 in total

1.  Psychotherapies in residency training.

Authors:  S Hamilton; L A Mellman; G O Gabbard; M E Thase; J C Markowitz
Journal:  J Psychother Pract Res       Date:  1999

2.  Assessment of subclinical symptoms and psychological well-being in depression.

Authors:  G A Fava; L Mangelli
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

3.  Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth.

Authors:  Beth D Kennard; Sunita M Stewart; Jennifer L Hughes; Robin B Jarrett; Graham J Emslie
Journal:  Cogn Behav Pract       Date:  2008-11-01

4.  Measurement-based care for unipolar depression.

Authors:  David W Morris; Madhukar H Trivedi
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

5.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

6.  Cognitive Therapy to Prevent Depressive Relapse in Adults.

Authors:  Jeffrey R Vittengl; Robin B Jarrett
Journal:  Curr Opin Psychol       Date:  2015-08-01

7.  Managing depression in primary care: achieving remission.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 8.  Remission from depression : a review of venlafaxine clinical and economic evidence.

Authors:  Donald Han; Edward C Y Wang
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Mixed Anxiety and Depression : Diagnosis and Treatment Options.

Authors:  D Bakish; R Habib; C L Hooper
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 10.  Prevalence and outcome of partial remission in depression.

Authors:  Richard Tranter; Claire O'Donovan; Praful Chandarana; Sidney Kennedy
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.